Impedimed Ltd (ASX: IPD) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Impedimed Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$40.77 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
2.04 billion
Earnings per share
-0.012
Dividend per share
N/A
Year To Date Return
-32.35%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Impedimed Ltd (ASX: IPD)
Latest News
⏸️ Investing
Why the shares of biotech star Impedimed Limited are rocketing today
⏸️ Investing
3 explosive healthcare shares to give your portfolio a boost
⏸️ Investing
Beat the market with these 3 growing healthcare shares
⏸️ Investing
Here's why these 4 ASX shares are storming higher today
⏸️ Investing
Here's why the shares of biotech Impedimed Limited are soaring today
⏸️ Investing
Why these 4 ASX shares are soaring today
⏸️ Investing
Does biotech Impedimed Limited have blockbuster potential?
⏸️ Investing
Here's why these 4 shares crashed on the market today
⏸️ Investing
Watch the Fed: rising US rates will support these Australian blue chips
⏸️ Investing
Is this company the next Nanosonics Ltd. or Impedimed Limited?
⏸️ Investing
10 S&P/ASX 300 stocks every investor needs on their watchlist
⏸️ Investing
Two small cap stocks I am banking on in 2015
Frequently Asked Questions
-
No, Impedimed does not pay shareholder dividends at this time.
-
Impedimed Limited listed on the ASX on 24 October 2007.
IPD ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Impedimed Ltd
Impedimed Ltd (ASX: IPD) is a global leader in the design and manufacture of medical devices that use bioimpedance spectroscopy (BIS) technologies in the non-invasive clinical assessment of fluid and tissue composition.
The company's products are typically used to assess and monitor lymphedema and heart failure, as well as to measure patients' tissue composition and fluid status. They also have general health applications in weight management, nutritional issues, and assessing bone content.
As well, Impedimed offers a cloud-based digital platform to manage patient data. The company is based in Australia and generates most of its revenue in North America.
IPD Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 03 Feb 2026 | $0.02 | $0.00 | 0.00% | 17,282,725 | $0.02 | $0.02 | $0.02 |
| 02 Feb 2026 | $0.02 | $0.00 | 0.00% | 9,278,075 | $0.02 | $0.02 | $0.02 |
| 30 Jan 2026 | $0.02 | $0.00 | 0.00% | 30,571,000 | $0.02 | $0.03 | $0.02 |
| 29 Jan 2026 | $0.02 | $-0.01 | -31.25% | 81,378,464 | $0.03 | $0.03 | $0.02 |
| 28 Jan 2026 | $0.03 | $0.00 | 0.00% | 4,312,109 | $0.03 | $0.03 | $0.03 |
| 27 Jan 2026 | $0.03 | $0.00 | 0.00% | 29,488,815 | $0.03 | $0.03 | $0.03 |
| 23 Jan 2026 | $0.03 | $0.00 | 0.00% | 813,604 | $0.03 | $0.03 | $0.03 |
| 22 Jan 2026 | $0.03 | $0.00 | 0.00% | 971,027 | $0.03 | $0.03 | $0.03 |
| 21 Jan 2026 | $0.03 | $0.00 | 0.00% | 1,980,613 | $0.04 | $0.04 | $0.03 |
| 20 Jan 2026 | $0.04 | $0.00 | 0.00% | 422,534 | $0.04 | $0.04 | $0.03 |
| 19 Jan 2026 | $0.03 | $0.00 | 0.00% | 198,930 | $0.03 | $0.04 | $0.03 |
| 16 Jan 2026 | $0.03 | $0.00 | 0.00% | 1,309,870 | $0.03 | $0.03 | $0.03 |
| 15 Jan 2026 | $0.03 | $0.00 | 0.00% | 10,012 | $0.03 | $0.03 | $0.03 |
| 14 Jan 2026 | $0.04 | $0.00 | 0.00% | 413,084 | $0.03 | $0.04 | $0.03 |
| 13 Jan 2026 | $0.03 | $0.00 | 0.00% | 261,395 | $0.04 | $0.04 | $0.03 |
| 12 Jan 2026 | $0.03 | $0.00 | 0.00% | 362,373 | $0.04 | $0.04 | $0.03 |
| 09 Jan 2026 | $0.03 | $0.00 | 0.00% | 482,914 | $0.04 | $0.04 | $0.03 |
| 08 Jan 2026 | $0.03 | $0.00 | 0.00% | 2,510,569 | $0.03 | $0.04 | $0.03 |
| 07 Jan 2026 | $0.03 | $0.00 | 0.00% | 454,298 | $0.03 | $0.04 | $0.03 |
| 06 Jan 2026 | $0.04 | $0.00 | 0.00% | 1,226,322 | $0.04 | $0.04 | $0.04 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 14 Jan 2026 | Andrew Grant | Issued | 100,563 | $3,569 |
Director remuneration.
|
| 14 Jan 2026 | Christine Emmanuel-Donnelly | Issued | 146,408 | $5,197 |
Director remuneration.
|
| 14 Jan 2026 | Janelle Delaney | Issued | 100,563 | $3,569 |
Director remuneration.
|
| 14 Jan 2026 | Fiona Bones | Issued | 100,563 | $3,569 |
Director remuneration.
|
| 03 Nov 2025 | Fiona Bones | Issued | 98,347 | $3,569 |
Director remuneration.
|
| 03 Nov 2025 | Janelle Delaney | Issued | 98,347 | $3,569 |
Director remuneration.
|
| 03 Nov 2025 | Christine Emmanuel-Donnelly | Issued | 143,182 | $5,197 |
Director remuneration.
|
| 03 Nov 2025 | Andrew Grant | Issued | 98,347 | $3,569 |
Director remuneration.
|
| 31 Jul 2025 | Christine Emmanuel-Donnelly | Issued | 474,084 | $14,838 |
Director remuneration.
|
| 31 Jul 2025 | Andrew Grant | Issued | 268,169 | $8,393 |
Director remuneration.
|
| 31 Jul 2025 | Janelle Delaney | Issued | 268,169 | $8,393 |
Director remuneration.
|
| 31 Jul 2025 | Fiona Bones | Issued | 268,169 | $8,393 |
Director remuneration.
|
| 26 May 2025 | Christine Emmanuel-Donnelly | Buy | 306,446 | $9,519 |
On-market trade.
|
| 22 Apr 2025 | Christine Emmanuel-Donnelly | Issued | 349,412 | $14,850 |
Director remuneration.
|
| 22 Apr 2025 | Andrew Grant | Issued | 197,647 | $8,399 |
Director remuneration.
|
| 22 Apr 2025 | Fiona Bones | Issued | 197,647 | $8,399 |
Director remuneration.
|
| 22 Apr 2025 | Janelle Delaney | Issued | 197,647 | $8,399 |
Director remuneration.
|
| 04 Mar 2025 | Christine Emmanuel-Donnelly | Buy | 318,116 | $13,414 |
On-market trade.
|
| 04 Mar 2025 | Christine Emmanuel-Donnelly | Buy | 545,000 | $20,832 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Parmjot Bains | Managing DirectorChief Executive Officer | Jan 2024 |
Dr Bains is a medical doctor with more than 30 years of healthcare experience including Pfizer and McKinsey across the United States, Asia, Middle East and Australia and also has 6 years Board/governance experience.
|
| Mr Andrew John Grant | Non-Executive Director | Sep 2023 |
Mr Grant has spent more than 20 years in gaining understanding and experience working with key US customers and across global healthcare markets. He has Strategic planning experience and delivery in healthcare working with healthcare organisations globally, including McKinsey and ResMed. He is also a member of Risk Committee.
|
| Mr McGregor Grant | Executive DirectorChief Financial Officer | Feb 2024 |
Mr Grant brings commercial and financial experience in growing global medical device businesses, most recently Nanosonics Limited. He has Board administration, governance and investor relations experience.
|
| Ms Christine Emmanuel-Donnelly | Non-Executive DirectorNon-Executive Chairman | Sep 2023 |
Ms Emmanuel-Donnelly brings 30 years in IP experience through commercialisation and strategic in-house intellectual property roles. She has more than 5 years in Board and healthcare governance experience. She is a member of the Risk Committee
|
| Ms Janelle Delaney | Non-Executive Director | Sep 2023 |
Ms Delaney has more than 30 years of project management and execution at IBM, with responsibility for the quality of delivery across Asia Pacific's portfolio of several thousand projects. She is a member of Risk Committee.
|
| Ms Fiona Bones | Non-Executive Director | Jun 2024 |
Ms Bones brings more than 30 years of experience in the finance, corporate governance and systems transformation. She has global governance experience gained as Vice President of Finance, International Controller of Google. She is Chair of the Risk Committee.
|
| Ms Leanne Ralph | Company Secretary | Jan 2015 |
-
|
| McGregor Grant | Chief Financial & Operating Officer/Executive Director |
-
|
|
| Steven Chen | Chief Medical Officer |
-
|
|
| Scott Savage | Chief Product Officer |
-
|
|
| Katie Newsome | Clinical Program Director |
-
|
|
| Leanne Ralph | Company Secretary |
-
|
|
| Ashley Munoz | Director Human Resources |
-
|
|
| Julie Kuhlken | Senior Director Marketing |
-
|
|
| Dennis Schlaht | SVP R&D and Technology |
-
|
|
| Scott Long | SVP Sales Key Accounts and Renewals |
-
|
|
| Mike Bassett | VP Business Development and Investor Relations |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Hsbc Custody Nominees (Australia) Limited | 261,631,361 | 12.89% |
| J P Morgan Nominees Australia Pty Limited | 138,619,651 | 6.83% |
| Citicorp Nominees Pty Limited | 118,098,388 | 5.82% |
| HSBC Custody Nominees (Australia) Limited i | 56,309,393 | 2.77% |
| Bnp Paribas Nominees Pty Ltd | 56,121,481 | 2.76% |
| Bnp Paribas Noms Pty Ltd | 32,741,215 | 1.61% |
| Moore Family Nominee Pty Ltd | 30,000,000 | 1.48% |
| Mr Stephen Edward Mahnken | 28,900,000 | 1.42% |
| Mr Stephen Edward Mahnken & Mrs Dior Leone Mahnken | 27,300,000 | 1.34% |
| Mr Hamish Alexander Jones | 26,410,134 | 1.30% |
| Mba Investments Pty Ltd | 22,490,990 | 1.11% |
| Bsd Pty Ltd | 19,000,000 | 0.94% |
| Bilgola Nominees Pty Limited | 16,978,161 | 0.84% |
| Pakasoluto Pty Limited | 16,011,422 | 0.79% |
| Acadia Park Pty Ltd | 14,374,048 | 0.71% |
| Mr Philip Joseph Bare | 13,641,648 | 0.67% |
| Mid Dig Investments Pty Ltd | 12,411,897 | 0.61% |
| Hme Soo Holdings Pty Ltd | 12,320,921 | 0.61% |
| Mr Gregory Wayne Brown & Mrs Stefanie Brown | 10,927,869 | 0.54% |
| Sunlora Pty Ltd | 10,050,010 | 0.50% |
